Clinical spectrum and features of activated phosphoinositide 3-kinase syndrome: Alarge patient cohort study

Tanya I. Coulter, MRCPI, Anita Chandra, PhD, FRCPath, Chris M. Bacon, PhD, FRCPath, Judith Babar, MRCP, FRCR, James Curtis, PhD, Nick Screaton, FRCP, FRCR, John R. Goodlad, MD, FRCPath, George Farmer, MD, Cathal Laurence Steele, MB, Timothy Ronan Leahy, MRCPI, Rainer Doffinger, PhD, FRCPath, Helen Baxendale, PhD, FRCPath, Jolanta Bernatoniene, PhD, J. David M. Edgar, FRCP, FRCPath, Hilary J. Longhurst, PhD, FRCPath, Stephan Ehl, MD, PhD, Carsten Speckmann, MD, Bodo Grimbacher, MD, PhD, Anna Sediva, MD, PhD, Tomas Milota, MD, Saul N. Faust, PhD, FRCPCH, Anthony P. Williams, PhD, FRCPath, Grant Hayman, FRCP, FRCPath, Zeynep Yesim Kucuk, MD, Rosie Hague, MRCP, FRCPH, Paul French, MD, MRCS, DipFMS, FRCPath, Richard Brooker, FRCPCH, Peter Forsyth, FRCPath, Richard Herriot, FRCP, FRCPath, Caterina Cancrini, MD, PhD, Paolo Palma, MD, PhD, Paola Ariganello, MD, Niall Conlon, PhD, FRCPath, Conleth Feighery, PhD, FRCPath, Patrick J. Gavin, MD, Alison Jones, PhD, FRCPCH, Kohsuke Imai, MD, PhD, Mohammad A. A. Ibrahim, PhD, FRCP, FRCPath, Ga sper Markelj, MD, Mario Abinun, MD, PhD, Fr ed eric Rieux-Laucat, PhD, Sylvain Latour, PhD, Isabelle Pellier, MD, PhD, Alain Fischer, MD, PhD, Fabien Touzot, MD, PhD, Jean-Laurent Casanova, MD, PhD, Anne Durandy, MD, PhD, Siobhan O. Burns, MD, PhD, Sinisa Savic, PhD, FRCPath, D. S. Kumararatne, FRCPath, DPhil (Oxon), Despina Moshous, MD, PhD, Sven Kracker, PhD, Bart Vanhaesebroeck, PhD, FMedSci, Klaus Okkenhaug, PhD, Capucine Picard, MD, PhD, Sergey Nejentsev, MD, PhD, Alison M. Condliffe, PhD, FRCP,* and Andrew James Cant, MD, FRCP, FRCPH* Dublin, Ireland;Cambridge, Newcastle, Inverness, Belfast, Bristol, London, Southampton, Surrey, Aberdeen, Newcastle upon Tyne, Leeds, Sheffield, Glasgow, andEdinburgh, UnitedKingdom; Freiburg,Germany;Prague,Czech Republic;Cincinnati, Ohio; Rome, Italy; Ljubljana, Slovenia; Paris and Angers, France; New York, NY; Chevy Chase, Md; and Tokyo, Japan